The tumor necrosis factor (TNF) inhibitors have set a high clinical standard for the treatment of psoriatic arthritis (PsA) that is challenging for emerging therapies to surpass. However, several newer therapies have made advances in the PsA market in recent years with the availability of the first interleukin (IL)-12/23 inhibitor, the first IL-17 inhibitor, and the first oral phosphodiesterase-4 inhibitor. With the goal of achieving minimal disease activity (MDA), rheumatologists use efficacy scores such as ACR20 and HAQ-DI to guide their prescription decisions. They also need to monitor for any drug-related side effects because most of the PsA therapies increase the risk of infection and malignancy. In this content, we identify key treatment drivers, discuss the safety signals that will alarm drug prescribers, create a simulation model that mimics rheumatologists’ prescribing rationale to project the market of a new therapy, and uncover three areas of unmet need in the PsA market.
- What are the treatment drivers and goals for PsA?
- What attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for PsA?
- What are the prevailing areas of unmet need and opportunity in PsA?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European rheumatologists for a hypothetical new PsA drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European rheumatologists fielded in December 2016
Key companies: AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Janssen, Merck, Novartis, Pfizer
Key drugs: Benepali, Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Xeljanz